Financials
Financial year 2025
DEBA PHARMA from Kortrijk, company number BE0434737865, closed financial year 2025 with a result of € 2.1 million after tax. For that financial year DEBA PHARMA recorded a gross margin of € 2.9 million and equity of € 6.2 million. Compared with financial year 2024, the result moved from € 1.8 million to € 2.1 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ 6.2 million
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.1 million
▲ 16% vs 2024
Profit after tax over the fiscal year.
€ 1.3 million
▼ 40% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.9 million paid out
89 % of the profit went to the shareholders, mostly to INFICOM (99 % of the shares). That is where the money ends up.
People and assets in 2025
1.2
▲ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 57,576
▲ 71% vs 2024
€ 48,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 147,929
▲ 53% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 20,833
▼ 71% vs 2024
Loans from banks and other lenders, long and short.
€ 168,345
▼ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 84,459
▲ 92% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,065,934 | € 2,183,357 | € 2,519,405 | € 2,918,801 | ▲ 16% |
| Profit after taxes | € 1,417,948 | € 1,527,317 | € 1,811,261 | € 2,098,156 | ▲ 16% |
| Equity | € 5,293,265 | € 5,710,582 | € 5,961,843 | € 6,199,999 | ▲ 4% |
| Total debts | € 565,248 | € 637,497 | € 368,220 | € 339,319 | ▼ 8% |
| Cash | € 2,565,353 | € 1,556,870 | € 2,253,276 | € 1,340,750 | ▼ 40% |
| Land & buildings | € 1,264,190 | € 1,181,486 | € 1,110,665 | € 1,103,322 | ▼ 1% |
| Retained profit | € 5,170,695 | € 5,588,012 | € 5,839,273 | € 6,077,429 | ▲ 4% |
| Dividend | € 660,000 | € 1,110,000 | € 1,560,000 | € 1,860,000 | ▲ 19% |
| Bank debt | € 170,833 | € 120,833 | € 70,833 | € 20,833 | ▼ 71% |
| Balance sheet total | € 5,897,893 | € 6,383,521 | € 6,361,960 | € 6,567,881 | ▲ 3% |
| Employees (FTE) | 0.5 | 0.5 | 0.7 | 1.2 | ▲ 0.5 |
Key figures of DEBA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DEBA PHARMA?
What happened at DEBA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- JOHAN DEJONGHE stepped down as director. NBB
- INFICOM BV stepped down as director. NBB
- VINCENT DEJONGHE stepped down as director. NBB
- KRISTOF DEJONGHE stepped down as director. NBB
- FREDERIK DEJONGHE stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.1 million (▲ 16% vs 2024). Source: NBB ↗
- JOHAN DEJONGHE became a director. NBB
- INFICOM BV became a director. NBB
In short
From € 1.4 million profit in 2022 to € 2.1 million profit in 2025.
Paid € 2.2 million in corporate taxes since 2022.
Best year ever: 2025, with € 2.1 million profit.
On average € 2.4 million of value added per employee in 2025.
A new publication or filing at DEBA PHARMA? We notify you, reason included.
Follow DEBA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of INFICOM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
DEBA PHARMAThe shares are held by INFICOM (98.7%).
Directors
According to the 2025 annual accounts
since 2025 · until 2031
Director · represented by BAEKELANDT INGRID
since 2025 · until 2031
VINCENT DEJONGHE
Director
since 2025 · until 2031
KRISTOF DEJONGHE
Director
since 2025 · until 2031
FREDERIK DEJONGHE
Director
since 2025 · until 2031
Shareholders
98.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Dumolinlaan 13
8510 Kortrijk
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 0434.737.865
- VAT number
- BE 0434.737.865
- Registered office
- Dumolinlaan 13, 8510 Kortrijk
- Names & denominations
- DEBA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 15 July 1988
- Peppol
- Active · Active since 23 Dec 2025
- Contact
- debapharma.be
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Overige gespecialiseerde groothandel in voedingswaren
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen